## 2 Materials and Methods
\begin{table}
\begin{tabular}{l l l l l l l l} \hline \hline  & **Nick Name** & **Parameters** & **Parents** & **Fine-Tuning** & **Open-Source** & **Company** \\ \hline
**OpenHermes 2.5** & OH (M1) & 7B &
\begin{tabular}{l} Miktral 7B \\ fine-tuned \\ \end{tabular} & Yes & Yes & - \\ \hline
**MythoMax 13B** & MM (M2) & 13B &
\begin{tabular}{l} MythoLogic \& \\ Huginn merge \\ \end{tabular} & No & Yes & - \\ \hline
**Noromaid Mixral** & NM (M3) & 8x7B * &
\begin{tabular}{l} Miktral 8x7B \\ fine-tuned \\ \end{tabular} & Yes & Yes & - \\ \hline
**Toppy M 7B** & TM (M4) & 7B &
\begin{tabular}{l} Multiple \\ Merge ** \\ \end{tabular} & No & Yes & - \\ \hline
**Chronomaid** & CS (M5) & 13B &
\begin{tabular}{l} Noromaid-13b \& \\ Chromos-13b-v2 \\ \end{tabular} & No & Yes & - \\ \hline
**Llama v2 70B Chat** & Llama (M6) & 70B & - & Yes & Yes &
\begin{tabular}{l} Meta (Menlo Park, \\ CA, USA) \\ \end{tabular} \\ \hline
**PaLM 2 Chat 32k** & Palm (M7) & 340B *** & - & - & No &
\begin{tabular}{l} Google (Santa Clara, \\ CA, USA) \\ \end{tabular} \\ \hline
**ChatGPT 3.5 Turbo** & CGPT (M8) & 20B *** & - & - & No &
\begin{tabular}{l} Open AI (San \\ Francisco, CA, \\ USA) \\ \end{tabular} \\ \hline
**Claude AI** & Claude (M9) & 130B *** & - & - & No &
\begin{tabular}{l} Anthropic (San \\ Francisco, CA, \\ USA) \\ \end{tabular} \\ \hline \hline \end{tabular}  
* Using new model architecture by Mistral AI, the model uses a high-quality mixture of experts (8 distinct models at 7B) it then chooses the two best performing for each task and generates an output based on a mixture. **Merge of Openchat 3.5 + Nous Capybara 7B + Zephyr 7B + AshhlimaRP-Mistral 7B using the new merge method, task_arithmetic, by mergekit. *** Estimated values, but not official ones, as the companies do not provide details on it.  
\end{table} 
Table 2: List of the 20 cases selected. For each case, the page and the diagnosis is provided, as described in [17]. \begin{table}
\begin{tabular}{l l} \hline \hline
**\# Case (Page)** & **Diagnosis** \\ \hline
**1 (page 14)** &
\begin{tabular}{l} Septic shock with multi-organ dysfunction, secondary to peritonitis due to intestinal perforation caused by biliary ileus. Bacteria due to Bacteroides vulgatus. Acute infero-posterior myocardial infarction in the previous context. Urgent percutaneous revascularisation of the middle right coronary artery. Moderate systolic dysfunction in the acute phase, mild at discharge. \\ \end{tabular} \\ \hline
**2 (page 24)** &
\begin{tabular}{l} Acute mechanical aortic prosthetic thrombosis. Cardiogenic shock secondary to cardiogenic shock. \\ Implantation of a mechanical aortic prosthesis ATS No18. Preserved LVEF at discharge. \\ \end{tabular} \\ \hline
**3 (page 36)** &
\begin{tabular}{l} Out-of-hospital CRA resuscitated by shockable rhythm. Idiopathic ventricular fibrillation: (a) \\ Angiographically normal coronary artery network. (b) No structural heart disease. (c) Good biventricular function. (d) Negative pharmacological tests to unmask channelopathy and vasospasm. \\ \end{tabular} \\ \hline
**4 (page 48)** &
\begin{tabular}{l} Eosinophilic or Loeffler’s endocarditis. Intraventricular thrombus. Hypereosinophilic syndrome. ASA triad. \\ Enoxaparin toxicity due to enoxaparin (SDRIFE). Prostatic adenocarcinoma. \\ \end{tabular} \\ \hline
**5 (page 62)** &
\begin{tabular}{l} Acute inferolateral myocardial infarction of thrombotic origin. Urgent revascularisation of right coronary artery. Preserved LV systolic function. Primary antiphospholipid syndrome with high-risk profile. \\ Abandonment of oral anticoagulant therapy. \\ \end{tabular} \\ \hline
**6 (page 134)** &
\begin{tabular}{l} Stage IV mammary neuroendocrine neoplasia. Carcinoid syndrome with cardiac involvement (severe \\ tricuspid insufficiency). Cardiac insufficiency of right predominance. Exitus. \\ \end{tabular} \\ \hline \hline \end{tabular}  
\end{table} 
Table 1: LLM models selected and main features of each of them. Nick name: used to reference the model in the experimental part.